The Gallay Laboratory

Publications

Research image

2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003

2012

Hopkins, S., DiMassimo, B, Rusnak, P., Heuman, D., Lalezari, J., Sluder, A.,Scorneaux, B., Mosier, S., Kowalczyk, P., Ribeill, Y., Baugh, J., and Gallay, P.A. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. In press, 2012.

Maskiewicz, R., Bobardt, M., Chatterji, U., Gunaseelan, S., Dezzutti, C.S., Penin, F., and Gallay, P.A. Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities. Antimicrobial Agents and Chemotherapy. In press, 2012.

Selvarajah, S. Chatterji, U., Kuhn, R., Kinney, Vasudevan, S. G., and Gallay, P.A. Development and evaluation of an enzyme-linked immunosorbent assay for Dengue capsid. The Open Virology Journal. In press, 2012.

2011

Gallay, P.A. Cyclophilin inhibitors: a novel class of promising host targeting anti-HCV agents. Immunologic Research. In press, 2011.

de Witte, L., Bobardt, M.D, Chatterji, U., van Loenen, F.B., Verjans, G.M., Geijtenbeek, T.B.H. and Gallay, P.A. HSV Neutralization by the Microbicidal Candidate C5A. PLoS One, 6(5):e18917, 2011.

Gregory, M.A., Moss, S. J., Coates, N., Foster, T., Bobardt, M., Chatterji, U., Gallay, P. A., Leyssen, P., Neyts, J., Nur-E-Alam, M., Piraee, M., Suthar, D., Warneck, T., Zhang, M.-Q., and Wilkinson, B. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrobial Agents and Chemotherapy, 55:1975-81, 2011.

Foster, T., Gallay, P.A., Stonehouse, N. and Harris, M. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. of Virol. 85:7460-4, 2011.

Chamoun AM, Chockalingam K, Bobardt M, Simeon R, Chang J, Gallay P., Chen Z. PD 404,182 is a virucidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus. Antimicrobial Agents and Chemotherapy, In press, 2011.

Moss SJ, Bobardt M, Leyssen P, Coates N, Chatterji U, Dejian X, Foster T, Liu J, Nur-e-Alam M, Suthar D, Yongsheng C, Warneck T, Neyts J, Gallay P., Wilkinson B, Gregory MA. Sangamides, a new class of cyclophilin inhibiting host targeted antivirals for treatment of HCV infection. Med. Chem. Commun. In press, 2011.

2010

Waller, H., Chatterji, U., Gallay, P., Parkinson, T., Targett-Adams, P. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A. J. Virol. Methods 165:202-10, 2010.

Bobardt, M.D., Chatterji, U., Schaffer, L., de Witte, L., and Gallay, P.A., Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrobial Agents and Chemotherapy, 54:2753-66, 2010.

Chatterji, U., Lim, P., Bobardt, M.D., Wieland, S., Cordek, D.G., Vuagniaux, G., Chisari, F., Cameron, C.E., Targett-Adams, P., Parkinson, T., and Gallay, P.A. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol., 53:50-6, 2010.

Chatterji, U., Bobardt, M.D., Lim, P., Gallay, P.A. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J. Gen. Virol. 91:1189-93, 2010.

Fischer, G., Gallay, P.A., Hopkins, S. Cyclophilin inhibitors for the treatment of hepatitis C virus infection. Curr. Opin. Investig. Drugs, 11:911-8, 2010.

Coelmont, L., Chatterji, U., Hanoulle, X., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., Bartenschlager, R., Gallay, P.A., Lippens, G., and Neyts, J. Debio 025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A. PLoS One, 5:e13687, 2010.

2009

Chatterji, U., Bobardt, M., Selvarajah, S., Yang,F., Tang, H. Sakamoto, N Vuagniaux, G., Parkinson, T., and Gallay, P. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 284:16998-7005, 2009. Epub Apr 20, 2009.

Gallay, P.A. Cyclophilin inhibitors. Clin. Liver Dis. 13:403-17, 2009.

2008

Cheng, G., Montero, A., Gastaminza, P., Whitten-Bauer, C., Wieland, S. F., Isogawa, M. Fredericksen, B., Selvarajah, S., Gallay, P., Ghadiri, R., and Chisari, F. V. A virocidal amphipathic alpha-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. 105:3088-93, 2008.

Bobardt, M., Cheng, G., de Witte, L., Selvarajah, S., Chatterji, U., Beer, B., Geijtenbeek, T. B. H., Chisari, F. V., and Gallay, P. A. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 105: 5525-30, 2008.

Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, A., Cielniak, I., Higersberger, J., Kierkus, J., Aeschlimann, C., Grosgurin, P., Nicolas-Métral, V., Dumont, J.-M., Porchet, H., Crabbé, R., and Scalfaro, P. The cyclophilin inhibitor Debio 025 shows potent anti-HCV effect in a double-blind, placebo-controlled study in HIV/HCV infected patients. Hepatology. 47:817-26 2008.

Ptak, R., Gallay, P. A., Jochmans, D., Halestrap, A. P., Ruegg, U. T., Pallansch, L. A., Bobardt, M. D., De Bethune, M.-P., Neyts, J., De Clercq,E., Dumont, J.-M., Scalfaro, P., Besseghir, K., Wenger, R. M., and Rosenwirth, B. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob. Agents Chemother. 52: 1302-07, 2008.

2007

Bobardt, M.D., Chatterji, U., Selvarajah, S., Van der Schueren B., David, G., Kahn, B. and Gallay, P.A. Cell-free HIV-1 transcytosis through primary genital epithelial cells. J. Virol. 81:395-405, 2007.

de Witte, L., Bobardt, M.D., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T.B.H., and Gallay, P. A. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. 104: 19464-9, 2007.

2006

Chatterji, U., Bobardt, M.D., Gaskill, P., Sheeter, D., Fox, H. and Gallay P.A. Trim 5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J. Biol. Chem. 281:37025-33, 2006.

2005

de Parseval, A., Bobardt, M.D., Chatterji, A., Chatterji, U., Elder, J.H, David, G., Zolla-Pazner, S., Farzan, M., Lee, T.-H. and Gallay, P.A. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J. Biol. Chem. 280:39493-504, 2005.

Chatterji, U., Bobardt, M.D., Stanfield, R., Ptak, R.G., Pallansch, L.A., Ward, P.A., Jones, M.J., Stoddart, C.A., Scalfaro, P., Dumont, J.M., Besseghir, K., Rosenwirth, B. and Gallay, P.A. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in owl monkey cells. J. Biol. Chem. 280:40293-300, 2005.

2004

Gallay, P.A. Syndecans and HIV-1 pathogenesis. Microbes and Infection 6:617-622, 2004.

Bobardt, M.D., Salmon, P., Wang, L., Esko, J.D., Gabuzda, D., Fiala, M., Trono, D., Van der Schueren, B., David, G. and Gallay, P.A. Contribution of proteoglycans to HIV-1 brain invasion. J. Virol. 78:6567-84, 2004.

Bobardt, M.D., Armand-Ugón, M., Clotet, I., Zhang, Z., David, G., Este, J.A. and Gallay, P.A. Effect of polyanion-resistance on HIV-1 infection. Virology 325:389-398, 2004.

2003

Bobardt, M.D., Saphire, A.C.S., Hung, H-C., Yu, X., Van der Schueren, B., Zhang, Z., David, G. and Gallay, P.A. Syndecan captures, protects and transmits HIV-1 to T-lymphocytes. Immunity 18:27-39, 2003.